1 / 17

Disclosures

Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and Rifampin Resistance in HIV Infected & HIV uninfected Pulmonary TB suspects: ACTG 5295/TBTC 34.

bruce-bean
Télécharger la présentation

Disclosures

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and Rifampin Resistance in HIV Infected & HIV uninfected Pulmonary TB suspects: ACTG 5295/TBTC 34 AF Luetkemeyer, C Firnhaber, MA Kendall, X Wu, D Benator, GH Mazurek, B Metchock, P Johnson, S Swindells, I Sanne, DV Havlir, B Grinsztejn, D Alland, on behalf of the ACTG A5295/TBTC 34 Study teams

  2. Disclosures • Instruments, cartridges and research grant support from Cepheid • Funding from NIH AIDS Clinical Trials Group (ACTG) and the CDC Tuberculosis Trials Consortium (TBTC)

  3. Background • GeneXpert MTB/RIF: automated real time PCR that diagnoses M. tuberculosis & identifies rifampin resistance in < 2 hours • Performance in high TB prevalence settings well characterized • Sensitivity of 1 Xpert: AFB+ 98-99% , AFB- ~60-70% • Specificity: 98-99% • Limited data for use in lower TB prevalence regions and in HIV coinfection

  4. Study Aims • Determine sensitivity and specificity of Xpert MTB/RIF assay overall and by AFB smear status • Evaluate Xpert performance by: • low TB prevalence (US) vs. higher TB prevalence (Brazil and South Africa) • HIV-infected vs. HIV-uninfected • Evaluate by Xpert performance for RIF resistance detection • Performance in setting of non-tuberculosis mycobacterial growth

  5. Study population • Pulmonary TB suspects • AFB+ sputum within 7 days of entry, or • Clinical suspicion of TB as evidenced by decision to send sputum for AFB smear/culture in addition to cough, fever, night sweats, or weight loss • TB treatment < 48 hours • Regions by TB prevalence • Low prevalence (US: target enrollment ≥ 70%) • Higher prevalence (Brazil & South Africa) • HIV-infected and uninfected • All participants underwent HIV testing

  6. Methods • 2 sputum samples for Xpert MTB/RIF testing (G4 cartridges) • Method of sputum collection (induced or expectorated) and processing (unprocessed orsedimented) prior to Xpert testing determined by local standard of care and not assigned by study • Xpert conducted within 7 days of sputum collection • Xpert testing at 2 central labs in US (Emory, UCSF) and at 1 lab in Rio de Janeiro, Brazil and 1 in Johannesburg, South Africa • All labs participated in external XpertQuality Assurance program • Xpert results compared to 2 sputum specimens, each evaluated with AFB smear, liquid and solid mycobacterial culture • Rifampin resistance by proportions method on Middlebrook agar • rpoB sequencing conducted on a specimen from each participant with ≥1 culture with TB growth

  7. Results • 720 of 994 participants had results for 2 AFB smears, 2 liquid and solid media mycobacterial cultures, and 2 Xpert available at time of analysis

  8. Results

  9. Sensitivity of 1 Xpert • No significant impact of region on sensitivity in AFB-/TB culture+

  10. Specificity of 1 Xpert • No significant impact of region on specificity

  11. Xpert Performance in HIV infection • HIV status did not significantly impact sensitivity or specificity

  12. Xpert in setting of NonTuberculosis Mycobacteria(NTM) Growth

  13. Discordance between Xpert & Culture • All discordance occurred in AFB smear negative specimens • 10 with Xpert TB+/ TB Culture negative:

  14. Xpert TB Negative /TB culture + • Of the 15 with 1stXpert TB negative, 2ndXpertwas TB+ in 3 out of 15 • 20% incremental yield of 2ndXpert test • In AFB-/TB culture+: • Sensitivity of 2 Xperts: 69.2% (27/39) • Sensitivity of 1 Xpert: 61.5% (24/39)

  15. Rifampin susceptibility • 3 Rifampin resistant specimens by culture-based DST: Xpert detected 3 out of 3 • Specificity: 98.8% (81/82) • One participant: Xpert RIF resistant / Culture RIF sensitive • 2 Xpert tests: 1 RIF resistant, 1 RIF sensitive • rpoB sequencing: wild type • NPV: 100% • PPV: 75% (n=4)

  16. Conclusions • Excellent performance for detection of TB including in low prevalence settings • Sensitivity AFB+100%, AFB- 61.5% • Specificity 98.9% overall, 99.3% in low prevalence • Performance not significantly impacted by region nor HIV status • Xpert detected 3 of 3 specimens rifampin resistant specimens by culture • Data support use of Xpert MTB/RIF in low prevalence settings and in HIV infection

  17. Acknowledgements • Study participants • Support from NIH, CDC, & Cepheid • ACTG 5295 Team • Tuberculosis Trials Consortium (TBTC) S34 Team • CDC Tuberculosis Lab • Participating ACTG & TBTC sites & site investigators

More Related